Literature DB >> 17072980

Gene expression profiles of hepatic cell-type specific marker genes in progression of liver fibrosis.

Yoshiyuki Takahara1, Mitsuo Takahashi, Hiroki Wagatsuma, Fumihiko Yokoya, Qing-Wei Zhang, Mutsuyo Yamaguchi, Hiroyuki Aburatani, Norifumi Kawada.   

Abstract

AIM: To determine the gene expression profile data for the whole liver during development of dimethylni-trosamine (DMN)-induced hepatic fibrosis.
METHODS: Marker genes were identified for different types of hepatic cells, including hepatic stellate cells (HSCs), Kupffer cells (including other inflammatory cells), and hepatocytes, using independent temporal DNA microarray data obtained from isolated hepatic cells.
RESULTS: The cell-type analysis of gene expression gave several key results and led to formation of three hypotheses: (1) changes in the expression of HSC-specific marker genes during fibrosis were similar to gene expression data in in vitro cultured HSCs, suggesting a major role of the self-activating characteristics of HSCs in formation of fibrosis; (2) expression of mast cell-specific marker genes reached a peak during liver fibrosis, suggesting a possible role of mast cells in formation of fibrosis; and (3) abnormal expression of hepatocyte-specific marker genes was found across several metabolic pathways during fibrosis, including sulfur-containing amino acid metabolism, fatty acid metabolism, and drug metabolism, suggesting a mechanistic relationship between these abnormalities and symptoms of liver fibrosis.
CONCLUSION: Analysis of marker genes for specific hepatic cell types can identify the key aspects of fibrogenesis. Sequential activation of inflammatory cells and the self-supporting properties of HSCs play an important role in development of fibrosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17072980      PMCID: PMC4100637          DOI: 10.3748/wjg.v12.i40.6473

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  66 in total

1.  L-cysteine administration prevents liver fibrosis by suppressing hepatic stellate cell proliferation and activation.

Authors:  Takashi Horie; Isao Sakaida; Fumihiko Yokoya; Megumi Nakajo; Ichiro Sonaka; Kiwamu Okita
Journal:  Biochem Biophys Res Commun       Date:  2003-05-23       Impact factor: 3.575

2.  Recent update on the PPAR alpha-null mouse.

Authors:  F J Gonzalez
Journal:  Biochimie       Date:  1997 Feb-Mar       Impact factor: 4.079

3.  Source of raised serum estrogens in male rats with portal bypass.

Authors:  G C Farrell; A Koltai; M Murray
Journal:  J Clin Invest       Date:  1988-01       Impact factor: 14.808

Review 4.  Resistance to growth hormone in children with chronic liver disease.

Authors:  J C Bucuvalas; J A Horn; S D Chernausek
Journal:  Pediatr Transplant       Date:  1997-08

5.  Regulation of the growth hormone receptor/binding protein, insulin-like growth factor ternary complex system in human cirrhosis.

Authors:  Anthony J Donaghy; Patric J D Delhanty; Ken K Ho; Roger Williams; Robert C Baxter
Journal:  J Hepatol       Date:  2002-06       Impact factor: 25.083

6.  Lipocalin 2 diminishes invasiveness and metastasis of Ras-transformed cells.

Authors:  Jun-ichi Hanai; Tadanori Mammoto; Pankaj Seth; Kiyoshi Mori; S Ananth Karumanchi; Jonathan Barasch; Vikas P Sukhatme
Journal:  J Biol Chem       Date:  2005-02-03       Impact factor: 5.157

7.  DAL-1/4.1B tumor suppressor interacts with protein arginine N-methyltransferase 3 (PRMT3) and inhibits its ability to methylate substrates in vitro and in vivo.

Authors:  Vinita Singh; Tina Branscombe Miranda; Wei Jiang; Adam Frankel; Martha E Roemer; Victoria A Robb; David H Gutmann; Harvey R Herschman; Steven Clarke; Irene F Newsham
Journal:  Oncogene       Date:  2004-10-14       Impact factor: 9.867

8.  Distribution of intrahepatic mast cells in various hepatobiliary disorders. An immunohistochemical study.

Authors:  M Yamashiro; W Kouda; N Kono; K Tsuneyama; O Matsui; Y Nakanuma
Journal:  Virchows Arch       Date:  1998-11       Impact factor: 4.064

9.  Hepatic chymase level in chronic hepatitis: co-localization of chymase with fibrosis.

Authors:  Shuji Shimizu; Katsuaki Satomura; Takumi Aramaki; Yasumi Katsuta; Teruo Takano; Yasukazu Omoto
Journal:  Hepatol Res       Date:  2003-09       Impact factor: 4.288

10.  Induction of cell death in activated hepatic stellate cells by targeted gene expression of the thymidine kinase/ganciclovir system.

Authors:  Nora Janoschek; Eddy van de Leur; Axel M Gressner; Ralf Weiskirchen
Journal:  Biochem Biophys Res Commun       Date:  2004-04-16       Impact factor: 3.575

View more
  19 in total

1.  Daily genetic profiling indicates JAK/STAT signaling promotes early hepatic stellate cell transdifferentiation.

Authors:  Ashley M Lakner; Cathy C Moore; Alyssa A Gulledge; Laura W Schrum
Journal:  World J Gastroenterol       Date:  2010-10-28       Impact factor: 5.742

2.  TRAP-seq identifies cystine/glutamate antiporter as a driver of recovery from liver injury.

Authors:  Amber W Wang; Kirk J Wangensteen; Yue J Wang; Adam M Zahm; Nicholas G Moss; Noam Erez; Klaus H Kaestner
Journal:  J Clin Invest       Date:  2018-04-30       Impact factor: 14.808

Review 3.  Extracellular matrix and liver disease.

Authors:  Elena Arriazu; Marina Ruiz de Galarreta; Francisco Javier Cubero; Marta Varela-Rey; María Pilar Pérez de Obanos; Tung Ming Leung; Aritz Lopategi; Aitor Benedicto; Ioana Abraham-Enachescu; Natalia Nieto
Journal:  Antioxid Redox Signal       Date:  2014-01-08       Impact factor: 8.401

4.  PPAR agonists regulate brain gene expression: relationship to their effects on ethanol consumption.

Authors:  Laura B Ferguson; Dana Most; Yuri A Blednov; R Adron Harris
Journal:  Neuropharmacology       Date:  2014-07-15       Impact factor: 5.250

5.  Pathophysiological characteristics of dimethylnitrosamine-induced liver fibrosis in acute and chronic injury models: a possible contribution of KLF5 to fibrogenic responses.

Authors:  Fumihiro Ohara; Aisuke Nii; Yojiro Sakiyama; Megumi Tsuchiya; Shinji Ogawa
Journal:  Dig Dis Sci       Date:  2007-12-20       Impact factor: 3.199

6.  Serial changes in expression of functionally clustered genes in progression of liver fibrosis in hepatitis C patients.

Authors:  Yoshiyuki Takahara; Mitsuo Takahashi; Qing-Wei Zhang; Hirotaka Wagatsuma; Maiko Mori; Akihiro Tamori; Susumu Shiomi; Shuhei Nishiguchi
Journal:  World J Gastroenterol       Date:  2008-04-07       Impact factor: 5.742

7.  Toxicogenomic biomarkers for liver toxicity.

Authors:  Naoki Kiyosawa; Yosuke Ando; Sunao Manabe; Takashi Yamoto
Journal:  J Toxicol Pathol       Date:  2009-04-06       Impact factor: 1.628

8.  NDRG2 ameliorates hepatic fibrosis by inhibiting the TGF-β1/Smad pathway and altering the MMP2/TIMP2 ratio in rats.

Authors:  Jiandong Yang; Jin Zheng; Lin Wu; Ming Shi; Hongtao Zhang; Xing Wang; Ning Xia; Desheng Wang; Xinping Liu; Libo Yao; Yan Li; Kefeng Dou
Journal:  PLoS One       Date:  2011-11-16       Impact factor: 3.240

9.  Gene expression in brain and liver produced by three different regimens of alcohol consumption in mice: comparison with immune activation.

Authors:  Elizabeth Osterndorff-Kahanek; Igor Ponomarev; Yuri A Blednov; R Adron Harris
Journal:  PLoS One       Date:  2013-03-29       Impact factor: 3.240

10.  The liver pharmacological and xenobiotic gene response repertoire.

Authors:  Georges Natsoulis; Cecelia I Pearson; Jeremy Gollub; Barrett P Eynon; Joe Ferng; Ramesh Nair; Radha Idury; May D Lee; Mark R Fielden; Richard J Brennan; Alan H Roter; Kurt Jarnagin
Journal:  Mol Syst Biol       Date:  2008-03-25       Impact factor: 11.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.